A novel glue consisting of human serum albumin (HSA) and citric acid derivative (CAD) was developed where the glue is named as CAD-A glue. In this adhesive, CAD works as a crosslinking reagent of HSA. For preparing crosslinking reagent CAD, using citric acid as a starting material, three carboxyl groups of a citric acid were modified with N-hydroxysuccinimide in the presence of 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide hydrochloride. From 1H-NMR spectrum, CAD with three active ester groups in a molecule was successfully synthesized with a high yield (more than 80%). The boding time of CAD-A glue to collagen-based casing was saturated within 15 minutes. The bonding strength of this glue to collagen-based casings increased with increasing of HSA concentration. The maximum bonding strength of CAD-A glue was a slightly low level compared to the bonding strength of cyanoacrylate adhesive and was 9 times higher than that of fibrin glue. The CAD-A glue showed excellent biocompatibility and high ability of wound closure similar to that of cyanoacrylate-based adhesive when glues were applied to the mouse skin. These results suggested that this developed adhesive had both tissue compatibility and bonding strength for use in clinical field.